Panagiotis Dalezis

Dr. Panagiotis Dalezis

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2009 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
DKDimitra Kovala-Demertzi
Dimitra Kovala-Demertzi
APAthanassios Papageorgiou
Athanassios Papageorgiou
LPLeuteris Papathanasis
Leuteris Papathanasis
AAAlexandros Alexandratos
Alexandros Alexandratos
PDPanagiotis Dalezis
Panagiotis Dalezis
MDMavroudis A. Demertzis
Mavroudis A. Demertzis

30 May 2022 in Dalton Transactions
Verified
Journal Article
Open access
PDF file
DVDespoina Varna
Despoina Varna
EGElena Geromichalou
Elena Geromichalou
AHAntonios G. Hatzidimitriou
Antonios G. Hatzidimitriou
RPRigini Papi
Rigini Papi
GPGeorge Psomas
George Psomas
PAPanagiotis Angaridis
Panagiotis Angaridis
Silver(i) complexes with NH2- and CF3-substituted thioamide ligands were synthesized, with the former exhibiting higher in vitro antibacterial and cytotoxic potency.

1 September 2020 in Journal of Inorganic Biochemistry
Verified
Journal Article
Closed access
DADespoina Anastasiadou
Despoina Anastasiadou
EGEleni Geromichalou
Eleni Geromichalou
ETEleni Tsavea
Eleni Tsavea
GPGeorge Psomas
George Psomas
AHAntonios Hatzidimitriou
Antonios Hatzidimitriou
PAParaskevas Aslanidis
Paraskevas Aslanidis

1 January 2023 in Molecules
Verified
Journal Article
Open access
PDF file
DVDespoina Varna
Despoina Varna
EGEleni Geromichalou
Eleni Geromichalou
GKGeorgia Karlioti
Georgia Karlioti
Rigini PapiRigini Papi
Rigini Papi
PDPanagiotis Dalezis
Panagiotis Dalezis
PAPanagiotis Angaridis
Panagiotis Angaridis
Ag(I) coordination compounds have recently attracted much attention as antiproliferative and antibacterial agents against a wide range of cancer cell lines and pathogens. The bioactivity potential of these complexes depends on their structural characteristics and the nature of their ligands. Herein, we present a series of four Ag(I) coordination compounds bearing as ligands the CH3-substituted thiadiazole-based thioamide 5-methyl-1,3,4-thiadiazole-2-thiol (mtdztH) and phosphines, i.e., [AgCl(mtdztH)(PPh3)2] (1), [Ag(mtdzt)(PPh3)3] (2), [AgCl(mtdztH)(xantphos)] (3), and [AgmtdztH)(dppe)(NO3)]n (4), where xantphos = 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene and dppe = 1,2-bis(diphenylphosphino)ethane, and the assessment of their in vitro antibacterial and anti-cancer efficiency. Among them, diphosphine-containing compounds 3 and 4 were found to exhibit broad-spectrum antibacterial activity characteristics against both Gram-(+) and Gram-(–) bacterial strains, showing high in vitro bioactivity with IC50 values as low as 4.6 μΜ. In vitro cytotoxicity studies against human ovarian, pancreatic, lung, and prostate cancer cell lines revealed the strong cytotoxic potential of 2 and 4, with IC50 values in the range of 3.1–24.0 μΜ, while 3 and 4 maintained the normal fibroblast cells’ viability at relatively higher levels. Assessment of these results, in combination with those obtained for analogous Ag(I) complexes bearing similar heterocyclic thioamides, suggest the pivotal role of the substituent groups of the thioamide heterocyclic ring in the antibacterial and anti-cancer efficacy of the respective Ag(I) complexes. Compounds 1–4 exhibited moderate in vitro antioxidant capacity for free radicals scavenging, as well as reasonably strong ability to interact with calf-thymus DNA, suggesting the likely implication of these properties in their bioactivity mechanisms. Complementary insights into the possible mechanism of their anti-cancer activity were provided by molecular docking calculations, exploring their ability to bind to the overexpressed fibroblast growth factor receptor 1 (FGFR1), affecting cancer cells’ functionalities.

1 January 2020 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
SSSofia Sagredou
Sofia Sagredou
PDPanagiotis Dalezis
Panagiotis Dalezis
NNNikolaos Nikoleousakos
Nikolaos Nikoleousakos
Michail NikolaouMichail Nikolaou
Michail Nikolaou
MVMaria Voura
Maria Voura
DTDimitrios Trafalis
Dimitrios Trafalis
Background: Topoisomerase II alpha (topII alpha ) maintains the topology of DNA in order to ensure the proper functioning of numerous DNA processes. Inhibition of topII alpha leads to the killing of cancer cells thus constituting such inhibitors as useful tools in cancer therapeutics. Triazolo[3,4-b]thiadiazole derivatives are known for their wide range of pharmacological activities while previous studies have documented their in vitro anticancer activity. The purpose of the current study was to investigate if these chemical compounds can act as topII alpha inhibitors in cell-free and cell-based systems. Materials and Methods: The MTT assay was performed in DLD-1, HT-29, and LoVo cancer cells so as to evaluate the antiproliferative activity of KA25, KA26, and KA39 triazolo[3,4-b]thiadiazole derivatives. The KA39 compound was tested as a potential topII alpha inhibitor using the plasmid-based topoisomerase II drug screening kit. The inhibitory effect of the three derivatives on topII alpha phosphorylation was studied in HT-29 and LoVo cancer cells according to Human Phospho-TOP2A/Topoisomerase II Alpha Cell-Based Phosphorylation ELISA Kit. Moreover, flow cytometry was utilized in order to explore apoptotic induction and cell cycle growth arrest, upon treatment with KA39, in DLD-1 and HT-29 cells, respectively. In silico studies were also carried out for further investigation. Results: All three triazolo[3,4-b]thiadiazole derivatives showed an in vitro antiproliferative effect with the KA39 compound being the most potent one. Our results indicated that KA39 induced both early and late apoptosis as well as cell cycle growth arrest in S phase. In addition, the compound blocked the relaxation of supercoiled DNA while it also inhibited topII alpha phosphorylation (upon treatment; P<0.001). Conclusion: Among the three triazolo[3,4-b]thiadiazole derivatives, KA39 was shown to be the most potent anticancer agent and catalytic inhibitor of topII alpha phosphorylation as well.

5 April 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
DTDimitrios Trafalis
Dimitrios Trafalis
SSSofia Sagredou
Sofia Sagredou
PDPanagiotis Dalezis
Panagiotis Dalezis
MVMaria Voura
Maria Voura
SFStella Fountoulaki
Stella Fountoulaki
VSVasiliki Sarli
Vasiliki Sarli
The fusion of 1,2,4-triazole and 1,3,4-thiadiazole rings results in a class of heterocycles compounds with an extensive range of pharmacological properties. A series of 1,2,4-triazolo[3,4-b]-1,2,4-thiadiazoles was synthesized and tested for its enzyme inhibition potential and anticancer activity. The results show that 1,2,4-triazolo[3,4-b]-1,2,4-thiadiazoles display potent anticancer properties in vitro against a panel of cancer cells and in vivo efficacy in HT-29 human colon tumor xenograft in CB17 severe combined immunodeficient (SCID) mice. Preliminary mechanistic studies revealed that KA25 and KA39 exhibit time- and concentration-dependent inhibition of Akt Ser-473 phosphorylation. Molecular modeling experiments indicated that 1,2,4-triazolo[3,4-b]-1,2,4-thiadiazoles bind well to the ATP binding site in Akt1 and Akt2. The low acute toxicity combined with in vitro and in vivo anticancer activity render triazolo[3,4-b]thiadiazoles KA25, KA26, and KA39 promising cancer therapeutic agents.